Prasugrel (clinical formulation) + Prasugrel (Orally Disintegrating Tablet [ODT])

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Sickle Cell Disease

Conditions

Sickle Cell Disease

Trial Timeline

Sep 1, 2011 → Oct 1, 2011

NCT ID

NCT01430091

About Prasugrel (clinical formulation) + Prasugrel (Orally Disintegrating Tablet [ODT])

Prasugrel (clinical formulation) + Prasugrel (Orally Disintegrating Tablet [ODT]) is a phase 1 stage product being developed by Eli Lilly for Sickle Cell Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01430091. Target conditions include Sickle Cell Disease.

What happened to similar drugs?

4 of 20 similar drugs in Sickle Cell Disease were approved

Approved (4) Terminated (9) Active (8)

✅CrizanlizumabNovartisApproved

✅crizanlizumabNovartisApproved

✅Voxelotor Oral TabletPfizerApproved

✅VoxelotorPfizerApproved

❌Prasugrel + PlaceboDaiichi SankyoPhase 3

❌ICA-17043Johnson & JohnsonPhase 3

❌Ticagrelor + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01430091	Phase 1	Completed	Sep 1, 2011	Oct 1, 2011	Sickle Cell Disease

Competing Products

20 competing products in Sickle Cell Disease

See all competitors

Product	Company	Stage	Hype Score
Prasugrel + Placebo	Daiichi Sankyo	Phase 3	32
Prasugrel	Daiichi Sankyo	Phase 1	29
Prasugrel + Placebo	Daiichi Sankyo	Phase 2	35
Prasugrel	Daiichi Sankyo	Phase 2	35
Lexiscan	Astellas Pharma	Phase 1	29
Placebo + Dalteparin	Eisai	Phase 2	35
tadalafil + placebo	Eli Lilly	Phase 2	27
Lidocaine Iv + Placebo	Johnson & Johnson	Phase 2	31
ICA-17043	Johnson & Johnson	Phase 3	32
Ticagrelor	AstraZeneca	Phase 1	29
Ticagrelor granule + Ticagrelor pediatric tablets + Ticagrelor pediatric tablets suspended in water + Ticagrelor immediate release (IR) tablets (Commercial tablet)	AstraZeneca	Phase 1	29
Ticagrelor + Placebo	AstraZeneca	Phase 2	35
Ticagrelor + Placebo	AstraZeneca	Phase 3	32
Brilinta + Placebo	AstraZeneca	Phase 3	32
Ticagrelor Dose 1a + Dose 2a + Ticagrelor Dose 1b + Dose 2b	AstraZeneca	Phase 2	35
vorinostat	Merck	Phase 2	27
Crizanlizumab + Placebo	Novartis	Phase 3	47
Crizanlizuamb + Standard of Care	Novartis	Phase 2	35
Crizanlizumab	Novartis	Approved	50
Hydroxyurea	Novartis	Phase 3	47